The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy.
OBJECTIVE To evaluate the antihypertensive effects of cilazapril , a new angiotensin-converting enzyme inhibitor , on clinic and ambulatory blood pressure ( ABP ) after first and last dose administrations . DESIGN Four weeks r and omized , double-blind , controlled trial of three regimens . SETTING Six hypertensive research clinics in Canada . PATIENTS After a two-week placebo run-in period , 130 patients aged 22 to 77 years with mild to moderate essential hypertension were r and omized and evaluated . Exclusion criteria were secondary hypertension , childbearing potential and other significant diseases . INTERVENTION Patients were assigned to cilazapril 2.5 mg ( 44 patients ) , cilazapril 5 mg ( 42 ) or placebo ( 44 ) . Fourteen patients in each group were further evaluated in a sub study by 24 h ABP monitoring . MAIN RESULTS Cilazapril in either dosage induced significant and similar antihypertensive effects on clinic blood pressure shortly after dosing ( 2 to 4 h ) , persisting during chronic treatment ; however , no relevant effect persisted at the end of dosing ( 24 h ) . After four weeks , at the end of dosing , 22 , 24 and 38 % of patients were clinical responders ( decrease in sitting diastolic blood pressure 10 mmHg or greater ) on placebo , 2.5 or 5 mg ( differences not significant ) . Conversely , both cilazapril regimens induced similar and significant ( P < 0.01 ) falls in mean 24 h ABP compared with placebo . Moreover , 7 , 50 and 48 % of patients exhibited a reduction in mean 24 h diastolic blood pressure 10 mmHg or greater on placebo , cilazapril 2.5 or 5 mg , respectively . Furthermore , both regimens induced adequate trough : peak ratios on ABP
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .